A Phase I/II Trial of TG01 and Gemcitabine as Adjuvant Therapy for Treating Patients with Resected Adenocarcinoma of the Pancreas
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 12 Oct 2017
At a glance
- Drugs TG 01 Targovax (Primary) ; Gemcitabine
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Targovax
- 12 Oct 2017 One-year data from modified cohort presented in a Targovax media release.
- 25 Sep 2017 According to a Targovax media release, main cohort of this trial has been completed recently and the company is planning read out from the second cohort in 2018.
- 12 Sep 2017 Results (n=19) presented at the 42nd European Society for Medical Oncology Congress.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History